Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Heparin and the Reduction of Thrombosis (HART) Trial
This study has been completed.
Sponsors and Collaborators: Stanford University
Pediatric Health Reserach Award
Information provided by: Stanford University
ClinicalTrials.gov Identifier: NCT00779558
  Purpose

Heparin is frequently used in central venous catheters (CVCs) in post-operative cardiac patients. It remains unclear if a heparin infusion, compared to a normal saline infusion, prevents thrombosis of CVCs after surgery. This study will answer the question: does a low-dose heparin infusion (10 units/kg/h) prevent thrombosis, compared to a normal saline infusion, in patients less than one year of age after cardiac surgery?


Condition Intervention
Thrombosis
Drug: Heparin sulfate infusion

MedlinePlus related topics: Blood Thinners Heart Surgery
Drug Information available for: Heparin
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Heparin and Catheter-Related Thrombosis in Neonates and Infants Following Cardiac Surgery

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Thrombosis

Secondary Outcome Measures:
  • Number of blood transfusions
  • Days to extubation
  • Cardiac ICU length of stay
  • Need for antibiotics
  • Laboratory values (coagulation studies and blood counts)
  • Chest tube output

Estimated Enrollment: 160
Study Start Date: November 2005
Estimated Study Completion Date: November 2007
Detailed Description:

Patients are contacted pre-operatively and their parents consented. The following criteria apply:

Inclusion criteria:

All infants < 1 year of age undergoing cardiac surgery at Lucile Packard Children's Hospital

Exclusion Criteria:

Known coagulopathy History of clinically significant bleeding (GI, cranial, pulmonary) Need for therapeutic heparinization ECMO

Randomization and blinding are performed in the Pharmacy. The intervention is initiated at the intensive care unit physician's discretion, generally within the 1st 24 hours post-operatively. The study is terminated when all catheters have been discontinued or at POD #14, whichever occurs first.

Thrombosis is demonstrated by echocardiogram or ultrasound performed at

1 - 3 days, 5 - 7 days, and 10 - 14 days after initiation of the study drug.

The following are calculations for statistical analysis:

Sample size determination - Using 2 - sided alpha = 0.05 and Beta = 0.2, and assuming a baseline thrombosis incidence of 20%, 160 patients are required to detect an effect size of 15%.

There are currently 96 patients enrolled.

  Eligibility

Ages Eligible for Study:   up to 1 Year
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All infants < 1 year of age undergoing cardiac surgery at Lucile Packard Children's Hospital & #xA

Exclusion Criteria:

  • Known coagulopathy
  • History of clinically significant bleeding (GI, cranial, pulmonary)
  • Need for therapeutic heparinization
  • ECMO
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00779558

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Pediatric Health Reserach Award
Investigators
Principal Investigator: Stephen J. Roth M.D., M.P.H. Stanford University
  More Information

Study ID Numbers: SU-11132007-879
Study First Received: October 22, 2008
Last Updated: October 23, 2008
ClinicalTrials.gov Identifier: NCT00779558  
Health Authority: United States: Institutional Review Board

Study placed in the following topic categories:
Embolism and Thrombosis
Embolism
Vascular Diseases
Heparin
Thrombosis
Calcium heparin

Additional relevant MeSH terms:
Fibrin Modulating Agents
Anticoagulants
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Hematologic Agents
Fibrinolytic Agents
Cardiovascular Diseases
Cardiovascular Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009